Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is advanced renal cell carcinoma best treated with temsirolimus, interferon α, or both?

Nature Clinical Practice Oncology volume 5, pages 16–17 (2008)Cite this article

boxed-textHudes G et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271–2281

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80: 1198–1220

    Article  CAS  Google Scholar 

  2. Patel PH et al. (2006) Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12: 7215–7220

    Article  CAS  Google Scholar 

  3. Amato R et al. (2006) A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC) [abstract]. J Clin Oncol 25 (Suppl): 5107

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Murphy, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Urology, New York University School of Medicine, 150 East 32nd Street, 2nd Floor, New York, NY 10016, USA william.huang@nyumc.org

Authors and Affiliations

  1. WC Huang is an Assistant Professor in Urology at New York University Medical Center, NY, USA.,

    William C Huang

Authors
  1. William C Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, W. Is advanced renal cell carcinoma best treated with temsirolimus, interferon α, or both?. Nat Rev Clin Oncol 5, 16–17 (2008). https://doi.org/10.1038/ncponc0986

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0986

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing